Table 2. Solicited systemic symptoms reported by the 30 females within 7 days after during the 7-day post-vaccination with human papillomavirus-16/18 AS04-adjuvanted vaccine.

Symptom	Type	HPV vaccination						Overall/subject		Overall/dose
		Dose 1		Dose 2		Dose 3
		n*	% (95% CI)	n*	% (95% CI)	n†	% (95% CI)	n*	% (95% CI)	n‡	% (95% CI)
Arthralgia	All	2	6.7 (0.8–22.1)	2	6.7 (0.8–22.1)	0	0.0 (0.0–11.9)	2	6.7 (0.8–22.1)	4	4.5 (1.2–11.1)
	Grade 3	0	0.0 (0.0–11.6)	1	3.3 (0.1–17.2)	0	0.0 (0.0–11.9)	1	3.3 (0.1–17.2)	1	1.1 (0.0–6.1)
Fatigue	All	6	20.0 (7.7–38.6)	7	23.3 (9.9–42.3)	4	13.8 (3.9–31.7)	10	33.3 (17.3–52.8)	17	19.1 (11.5–28.8)
Fever	All	1	3.3 (0.1–17.2)	1	3.3 (0.1–17.2)	0	0.0 (0.0–11.9)	2	6.7(0.8–22.1)	2	2.2 (0.3–7.9)
Gastro-intestinal	All	1	3.3 (0.1–17.2)	3	10.0 (2.1–26.5)	0	0.0 (0.0–11.9)	4	13.3 (3.8–30.7)	4	4.5 (1.2–11.1)
Headache	All	6	20.0 (7.7–38.6)	4	13.3 (3.8–30.7)	2	6.9 (0.8–22.8)	8	26.7 (12.3–45.9)	12	13.5 (7.2–22.4)
	Grade 3	0	0.0 (0.0–11.6)	1	3.3 (0.1–17.2)	0	0.0 (0.0–11.9)	1	3.3 (0.1–17.2)	1	1.1 (0.0–6.1)
Myalgia	All	5	16.7 (5.6–34.7)	3	10.0 (2.1–26.5)	2	6.9 (0.8–22.8)	7	23.3 (9.9–42.3)	10	11.2 (5.5–19.7)
	Grade 3	1	3.3 (0.1–17.2)	1	3.3 (0.1–17.2)	0	0.0 (0.0–11.9)	1	3.3 (0.1–17.2)	2	2.2 (0.3–7.9)
Rash	All	0	0.0 (0.0–11.6)	0	0.0 (0.0–11.6)	1	3.4 (0.1–17.8)	1	3.3 (0.1–17.2)	1	1.1 (0.0–6.1)

Footnotes as in Table 1. No cases of grade 3 fatigue, fever, gastrointestinal reaction, and rash and no cases of urticaria were reported.